The entire amino acid sequence of human cytomegalovirus (HCMV) 150K matrix phosphoprotein (pp150), consisting of 1048 amino acid residues, was divided into 95 overlapping 20 amino acid peptides which were synthesized on polyethylene rods. The rods were subjected to ELISA with pooled anti-HCMV-positive and anti-HCMV-negative sera. Four peptides recognized by the anti-HCMV-positi~,e pool only were synthesized by the solid-phase method and their reactivity in a conventional ELISA, using a panel of 14 individual anti-HCMV-negative and 20 anti-HCMVpositive antisera, was evaluated; three peptides were found to be specifically reactive. Results obtained with one of these peptides (residues 595 to 614) in ELISA showed a good correlation with those obtained using a routinely performed complement fixation test.
Introduction
Human cytomegalovirus (HCMV), a betaherpesvirus, is widespread in human populations and is a causative agent of persistent asymptomatic infections. However, HCMV is a major pathogen in immunosuppressed individuals, mainly in transplant recipients and AIDS patients. Moreover, primary infection of women during pregnancy can cause congenital infection leading to severe damage of the foetus. HCMV may cause less severe complications as a result of primary exogenous infection or secondary virus reactivation (Durack, 1984; Myers et al., 1982; Stagno et al., 1982; Schmitz et al., 1986) . Generally, HCMV infection can be diagnosed by various approaches. Virus isolation, revealed by a characteristic c.p.e, in human fibroblast cell culture, is the most sensitive method for detection of HCMV viraemia, although methods based on detection of viral antigens or DNA are also being used (Griffiths, 1989) . However, evaluation of antibody titres to HCMV in patient sera remains an important diagnostic approach.
In recent years the HCMV structural proteins have been defined to a substantial extent and their genes localized in the viral genome . Several envelope glycoproteins and their coding regions have been identified and their role as targets in the immune response has been investigated (Britt et al., 1988; Cranage et al., t988) . Another group of structural 0000-9948 © 1991 SGM proteins, matrix phosphoproteins, appear to be highly immunogenic and antibodies directed against them may be of diagnostic value. At least nine minor phosphoproteins and three predominant phosphoproteins, pp28, pp65 and pp 150, are recognized by human sera (Landini et al., 1985) . Antibodies against pp65 appear in the early phase of primary infection and are followed by antibodies to ppl50 (Landini et al., 1988) ; genes encoding both proteins have been identified (Ruger et al., 1977; Jahn et al., 1987) , opening the way for production of engineered recombinant polypeptides (Landini et al., 1990) or synthetic peptides.
Synthetic peptides corresponding to immunodominant antigenic determinants of proteins can be used for the detection of antibodies to a parent protein (Van Regenmortel et al., 1988) . A variety of computer algorithms have been developed to localize antigenic determinants of proteins (Geysen et al., 1987a) ; however, computer prediction of antigenic determinants can only localize regions with a predisposition to be determinants and does not provide an exhaustive list of epitopes (Middeldorp & Meloen, 1988) . To obtain a complete picture of serologically relevant regions, a set of overlapping peptides covering the entire amino acid sequence of a protein must be synthesized and their serological reactivity evaluated. Since the standard synthesis of hundreds of peptides is costly and timeconsuming, Geysen et al. have developed an epitope mapping procedure based on the synthesis of peptides on chemically activated plastic rods (Geysen et al., 1987b , Middeldorp & Meloen, 1988 .
In this paper we describe the application of the method of Geysen et al. to the evaluation of serologically relevant antigenic determinants of HCMV ppl50.
Methods
Peptide synthesis on polyethylene pins. The sequence of HCMV strain AD169 ppl50 (Jahn et al., 1987) was divided into 95 20 amino acid stretches with a nine amino acid overlap between adjacent peptides. These overlapping peptides and a peptide derived from the EpsteinBarr virus (EBV) EBNA-I sequence, known to be highly reactive with EBV-positive sera (Dillner et al., 1984) , were synthesized by modified solid-phase synthesis on chemically activated polyethylene pins using the Fmoc/t-Bu protection strategy (Geysen et al., 1987 b) . Monitoring of condensation was performed using bromophenol blue (Krchfifik & V~gner, 1990) .
Peptide synthesis on resin. Peptides were prepared by continuous flow solid-phase multiple peptide synthesis (Krchfi~k et al., 1987 (Krchfi~k et al., , 1989 on p-methylbenzhydrylamine resin using the Fmoc/t-Bu protection strategy. The coupling reaction was monitored using bromophenol blue (Krchfifik & Vfigner, 1990) . Side chain-protecting groups were removed using trifluoroacetic acid and peptides were split off from the resin in liquid hydrogen fluoride. The crude peptides were purified by gel filtration on Sephadex G 15 and shown to be of satisfactory amino acid composition.
lmmunoscreening of peptides on polyethylene pins. Each pin was incubated with 500 ~tl bicarbonate buffer pH 9.6 containing 1% bovine serum albumin (BSA) for 1 h to prevent non-specific adsorption of immunoglobulins. The pins were washed in a 96-weU Teflon plate with agitation, then incubated for 1 h with 200 ~tl sera diluted 1 : 500 in phosphate-based dilution buffer (pH 7.2) containing 0.36 M-NaC1, 1 ~ BSA and 1 ~ Triton X-100, washed five times and incubated with swine anti-human IgG conjugated with horseradish peroxidase (Sevac) for t h. After five washings the colour reaction was developed by incubation with o-phenylenediamine (OPD) (Sevac) and hydrogen peroxide in citrate buffer pH 5-0, and stopped by adding 200 ktl 2 Msulphuric acid. All operations were done at room temperature. Before the next immunoscreening, antibodies bound to the pins were removed as described by Geysen et al. (1987) .
ELISA. ELISAs with four selected peptides were carried out by a standard solid-phase method. The peptides were used either in a free form or after coupling to BSA (Serva) with glutaraldehyde. Microelisa plates (from Novogen for free peptides, or from Dynatech for BSAconjugated peptides) were coated with peptide (1 ktg/well) in bicarbonate buffer (pH 9.6) for 1 h at room temperature. Free binding sites on the plates were saturated using 1 ~ BSA prepared in the same buffer. After 1 h at room temperature, the BSA solution was removed, tested sera diluted 1:50 were added and the mixture was incubated at room temperature for 1 h. After several washings, peroxidase-conjugated swine antibody to human IgG diluted 1:2500 was added. The colour reaction was developed by incubation with OPD. The composition of the buffers and details of the ELISA procedure have been described elsewhere (Vestergaard et al., 1977) . 
Results

Peptide-scanning analysis
The entire amino acid sequence of ppl50, which is composed of 1048 amino acids, was represented by 95 20 amino acid peptides, synthesized on polyethylene rods; each peptide overlapped the previous one by nine amino acids. The amino acid sequence of the 96th peptide was derived from the EBV EBNA-1 protein and served as a control antigen. The use of this peptide in the study of the serology of EBV infections is well documented (DiUner et al., 1984) . The 95 polyethylene rods with covalently bound, overlapping 20 residue peptides were tested for their reactivity with pools of 20 anti-HCMV-positive and 14 anti-HCMV-negative human sera, both diluted 1:500. The results are shown in Fig. 1 . Of the peptides, 12 were recognized by the anti-HCMV-positive pool only (1, 40, 49, 51, 53, 55, 56, 57, 83, 87, 88 and 91) . Some peptides reacted with both anti-HCMV-positive and -negative pools whereas other peptides reacted with the anti-HCMV-negative pool only.
The EBV EBNA-l-derived peptide (96), tested with anti-EBV-positive sera, gave the highest response and did not react with anti-EBV-negative sera (Fig. 1) . 
Use of selected peptides in conventional ELISA
Since the polyethylene rods had not been designed for routine screening, four peptides were selected for synthesis on resin and subsequent testing in a conventional ELISA. Peptides 55, 57, 87 and 91 (Table 1) were chosen on the basis of their strong reactivity with pooled anti-HCMV-positive sera and their lack of reactivity with anti-HCMV-negative sera. The synthetic peptides, either free or conjugated to BSA with glutaraldehyde, were coated onto the surface of ELISA microtitre plates. In a conventional ELISA, pooled human anti-HCMV-positive sera recognized only three of the BSA-conjugated or unconjugated peptides (55, 57 and 87; Fig. 2) .
Peptides recognized by the anti-HCMV-positive sera pool were examined in a conventional ELISA using a panel of 20 anti-individual anti-HCMV-positive and 14 -negative sera. The pool of anti-HCMV-positive sera was used as a positive standard reagent, its absorbance (A) in the assay being taken as 1000 and the values of all other sera being expressed relative to this standard. Peptides 55, 57 and 87 were used both in the BSA-conjugated and the free form. Normalized ELISA values for the reactivity of diluted sera (1:50) with BSA-conjugated peptides are shown in Fig. 3 ; average A values, standard deviations (S.D.) and cutoff values of conjugated and free peptides are presented in Table 2 . The cut-off values were calculated from the A readings obtained with anti-HCMV-negative sera and were set as the mean + 3 S.D. The highest positive score was displayed by peptide 55 conjugated to BSA (100~), whereas peptides 57 and 87 reacted with 90 ~ and 35 ~o of anti-HCMV-positive sera, respectively. Similarly, when used in the unconjugated form, peptide 55 reacted with the highest proportion of anti-HCMV-positive sera (68~), whereas peptides 57 and 87 reacted with 2 6~ and 16~ respectively. Interestingly, some sera which recognized peptide 55 weakly reacted strongly with peptide 57 (sera 21, 22 and 30) or with peptide 87 (sera 18, 25 and 27; Fig. 3 ). The reactivity of peptides with sera with the lowest complement-fixation titres (sera 31 to 34; Fig 3) was generally less clear cut but, with respect to the A values determined using BSA-conjugated peptide 55, can still be considered weakly positive. In addition, most anti-HCMV-positive sera recognized BSA-conjugated peptides better than unconjugated peptides and, furthermore, the A values of anti-HCMV-negative sera exhibited smaller fluctuations with BSA-conjugated peptides, leading to a reduction in the S.D. and a lowering of the cut-off value. Therefore it can be concluded that our BSA-conjugated peptides are more reliable as antigens for routine serological diagnosis.
Discussion
We have identified several regions within HCMV pp150 which contain epitopes recognized by anti-HCMVpositive but not -negative human sera. One of them, representing amino acids 595 to 614 (peptide 55), reacted with all 20 anti-HCMV-positive sera tested when conjugated to BSA. Thus, its reactivity in ELISA was in good agreement with the results of a conventional complement fixation test.
In the present paper, the immunogenic regions of HCMV pp150 were analysed using 20 amino acid peptides sequentially synthesized on polyethylene rods (Geysen et al., 1987b) . A control antigen, the EBV EBNA-l-derived peptide whose antigenicity is already well established (Dillner et al., 1984) , was included in the synthesis and displayed strong reactivity with anti-EBVpositive human sera (Fig. 1) . Interestingly, one peptide (91) of the four peptides found to be reactive on polyethylene rods was not recognized when prepared by solid-phase synthesis on resin and used in a conventional ELISA on polystyrene microtitre plates, either in unconjugated or BSA-conjugated form. This finding indicates that not all peptides reactive on polyethylene rods are necessarily reactive when coated onto polystyrene. We observed a similar discrepancy when synthesizing the reportedly major EBV capsid antigenderived peptide, identified by Middeldorp & Meloen (1988) as representing an immunodominant epitope of this protein. This may be associated somehow with the topology of the peptide and its accessibility for reaction with antibody. The peptides are attached to polyethylene rods by their carboxy termini and to BSA by their amino termini, but their spatial arrangement when attached directly to a polystyrene surface is difficult to predict.
Peptide 55 probably contains (one of) the major continuous antigenic epitope(s) of pp150. The other reactive peptides, 57 and 87, may represent areas with minor determinants because they reacted with only some sera, albeit in some cases very strongly (peptide 57 with sera 21, 22 and 30, and peptide 87 with sera 18, 25 and 27, respectively; Fig. 3 ). This may reflect individual variability in antibody response against different epitopes of a particular polypeptide. A similar variation in the antibody response to minor antigenic determinants was also noted by Middeldorp & Meloen (1988) , who worked with a panel of synthetic peptides covering the whole length of a major capsid protein of EBV. As peptides 55 and 57 are separated by only two amino acids, the region of ppl50 represented by these peptides is probably recognized by the majority of anti-HCMV ppl50-positive sera. Further detailed study of this part of pp 150 using an extended panel of sera is needed.
Whether some other amino acid sequences of pplS0 could behave as immunoreactive or even immunodominant epitopes remains questionable. The possibility still exists that several other regions of the protein that have not yet been synthesized on resin, and thus not subjected to detailed study with a panel of sera, may contain an immunoreactive region. In addition, it is possible that when using another method of coupling the peptides to BSA (using the carboxy termini), other peptides would appear to be immunoreactive.
The mapping method, as well as the entire peptidebased approach to the construction of diagnostic systems, does not address the question of conformational epitopes, which also may serve as major immunogenic entities of a given protein (Geysen et al., 1987b; Van Regenmortel et al., 1988) . In this respect an approach employing recombinant bacterial products as antigens would seem to be more appropriate; in the case of HCMV pp150 (and also pp65) such products are already available and large-scale screening of sera with these products has been carried out (Landini et al., 1990) . On the other hand some immunodominant epitopes may be hidden in the native protein and thus not available for interaction with antibodies present in anti-HCMVpositive sera. Peptides covering such a region were derived from gp41 of human immunodeficiency virus type 1 and shown to detect early seroconversion samples more reliably than the whole virion-based ELISA (Narvanen et al., 1988) . Comparison of our peptidebased ELISA with that based on recombinant protein will be the subject of further investigation.
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